The shares in Piramal Pharma Limited traded at ₹244.98 down by INR 10.86 or 4.24 percent on NSE today at 12.05.

Piramal Pharma Limited reported strong financial results for Q2 and H1 FY25, ended September 30, 2024, with consolidated revenue growth of 17 percent YoY to INR 2,242 crore. This increase was largely driven by the robust performance of the Contract Development and Manufacturing Organization (CDMO) segment, which grew 24 percent year over year.

• Read also: Piramal Pharma Q2 net profit 4x to ₹23 crore; revenues of INR 2,242 crore

The company’s EBITDA grew 28 percent YoY to Rs 403 crore, improving its EBITDA margin to 18 percent, up from 16 percent in Q2 FY24. This increase reflects strategic cost optimizations and a favorable revenue mix. In addition, net profit after tax increased by 350 per cent year-on-year to £23bn, thanks to strong operational efficiency and strategic initiatives.

Piramal Pharma’s CDMO business led the growth with increased demand for generic APIs and a An $80 million expansion at its Lexington facilitywhich aims to double sterile fill finish capacity by FY27. Meanwhile, the Complex Hospital Generics (CHG) segment saw revenue growth of 9 percent, supported by increasing demand for inhalation anesthesia products in the US and emerging markets, along with ongoing capacity expansions at Dahej and Digwal.

• Read also: Piramal Pharma invests 80 million dollars in expansion of the facility in Kentucky

CEO Nandini Piramal emphasized the company’s long-term goal of achieving $2 billion in revenue and a 25 percent EBITDA margin by FY30, leveraging expansion plans and increasing focus on differentiated and specialty products.